Data Presented for Tryton's Side Branch System

May 25, 2010—Tryton Medical, Inc. (Durham, NC) announced results for the company's Tryton Side Branch stent system at a symposium during the EuroPCR 2010 conference in Paris. Robert-Jan Van Geuns, MD, presented data from the Rotterdam-Poznan Series, a two-center consecutive series that included 100 lesions from 96 patients who were followed for 6 months. The results demonstrated a procedural success rate of 94% and a target vessel revascularization rate of 4% at 6 months. The stented artery was a left main coronary artery in 8% of the cases examined in the series.

Maciej Lesiak, MD, presented acute data from the E-TRYTON 150 study, a multicenter consecutive registry performed at eight European centers. The study enrolled 150 consecutive patients who received the Tryton Side Branch stent. The E-TRYTON registry results showed a procedural success rate of 98.5% for treatment of bifurcation lesions with a wide distribution of angles and anatomic locations, including the left main coronary artery.

According to the company, the Tryton Side Branch stent system demonstrated excellent 6-month clinical results in a first-in-man study of the system in 30 patients, with no restenosis occurring in the side branch artery.

The Tryton Side Branch stent system is designed to offer a dedicated strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. The device features a cobalt-chromium stent, which is deployed in the side branch artery using a standard single-wire, balloonexpandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel. The stent system has received CE Mark approval and is commercially available in 12 European countries. The device is not approved in the United States.